Zydus Cadila on Thursday said it is seeking permission from Drugs Controller General of India (DCGI) to initiate human clinical trials for monoclonal antibodies cocktail for treatment of Covid-19.

"Zydus is currently seeking permission to initiate phase 1/3 human clinical trials from the DCGI... ZRC-3308, a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild Covid-19," Cadila Healthcare said in a regulatory filing.